These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 30329175)

  • 1. Cost-minimization analysis in the Indian subcontinent for treating Guillain Barre Syndrome patients with therapeutic plasma exchange as compared to intravenous immunoglobulin.
    Maheshwari A; Sharma RR; Prinja S; Hans R; Modi M; Sharma N; Marwaha N
    J Clin Apher; 2018 Dec; 33(6):631-637. PubMed ID: 30329175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome.
    Winters JL; Brown D; Hazard E; Chainani A; Andrzejewski C
    BMC Health Serv Res; 2011 May; 11():101. PubMed ID: 21575219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomics of therapy for Guillain-Barré syndrome: plasma exchange and intravenous immunoglobulin.
    Tsai CP; Wang KC; Liu CY; Sheng WY; Lee TC
    J Clin Neurosci; 2007 Jul; 14(7):625-9. PubMed ID: 17532498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency.
    Oczko-Walker M; Manousakis G; Wang S; Malter JS; Waclawik AJ
    J Clin Neuromuscul Dis; 2010 Dec; 12(2):55-61. PubMed ID: 21386771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comment on "Pharmacoeconomics of therapy for Guillain-Barré syndrome: plasma exchange and intravenous immunoglobulin".
    Buenz EJ
    J Clin Neurosci; 2009 Aug; 16(8):1110; author reply 1111. PubMed ID: 19467870
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of Guillain-Barré syndrome: a cost-effectiveness analysis.
    Nagpal S; Benstead T; Shumak K; Rock G; Brown M; Anderson DR
    J Clin Apher; 1999; 14(3):107-13. PubMed ID: 10540364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmapheresis treatment in Guillain-Barré syndrome: potential benefit over IVIg in patients with axonal involvement.
    Dada MA; Kaplan AA
    Ther Apher Dial; 2004 Oct; 8(5):409-12. PubMed ID: 15663537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin for Guillain-Barré syndrome.
    Hughes RA; Raphaël JC; Swan AV; van Doorn PA
    Cochrane Database Syst Rev; 2001; (2):CD002063. PubMed ID: 11406030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and cost effectiveness of current therapies in Guillain Barre syndrome.
    Mehndiratta MM; Chowdhury D; Goel V
    J Assoc Physicians India; 2001 Apr; 49():459-69. PubMed ID: 11762620
    [No Abstract]   [Full Text] [Related]  

  • 10. Intravenous immunoglobulin for Guillain-Barré syndrome.
    Hughes RA; Swan AV; van Doorn PA
    Cochrane Database Syst Rev; 2010 Jun; (6):CD002063. PubMed ID: 20556755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immunoglobulin for Guillain-Barré syndrome.
    Hughes RA; Raphaël JC; Swan AV; van Doorn PA
    Cochrane Database Syst Rev; 2006 Jan; (1):CD002063. PubMed ID: 16437439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immunoglobulin for Guillain-Barré syndrome.
    Hughes RA; Raphaël JC; Swan AV; Doorn PA
    Cochrane Database Syst Rev; 2004; (1):CD002063. PubMed ID: 14973982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost analysis of plasma-exchange therapy for the treatment of Guillain-Barré syndrome. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome.
    Espérou H; Jars-Guincestre MC; Bolgert F; Raphaël JC; Durand-Zaleski I
    Intensive Care Med; 2000 Aug; 26(8):1094-100. PubMed ID: 11030166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.
    Lancet; 1997 Jan; 349(9047):225-30. PubMed ID: 9014908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features and real-world outcomes of Guillain-Barré syndrome in the Philippines.
    I Espiritu A; Separa KJNJ; Milla FJC; Adiao KJB; Leochico CFD; Jamora RDG
    Neurol Res; 2021 Dec; 43(12):995-1004. PubMed ID: 34229572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of immunotherapy in Guillain-Barré syndrome: understanding the mechanism of action.
    Shahrizaila N; Yuki N
    Expert Opin Pharmacother; 2011 Jul; 12(10):1551-60. PubMed ID: 21473704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of Guillain-Barré Syndrome].
    Nomura K
    Brain Nerve; 2015 Nov; 67(11):1397-410. PubMed ID: 26560955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial.
    Walgaard C; Jacobs BC; Lingsma HF; Steyerberg EW; Cornblath DR; van Doorn PA;
    J Peripher Nerv Syst; 2018 Dec; 23(4):210-215. PubMed ID: 30151941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional outcomes following inpatient rehabilitation of Guillain-Barré syndrome patients: Intravenous immunoglobulins versus plasma exchange.
    Bondi M; Engel-Haber E; Wolff J; Grosman-Rimon L; Bloch A; Zeilig G
    NeuroRehabilitation; 2021; 48(4):543-551. PubMed ID: 34024788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison on therapeutic effect of plasma exchange and intravenous immunoglobulin for Guillian-Barre syndrome.
    Ye Y; Li SL; Li YJ
    Transfus Med; 2015 Apr; 25(2):79-84. PubMed ID: 25515056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.